The DERMA study evaluated the efficacy of the tumor-specific antigen MAGE-A3, which is expressed by various tumors, including melanoma, combined with an immunostimulant in order to enhance the immune response against the tumor [22]. The gene discussed is MAGEA3; the disease is neoplasm.